Rhumbline Advisers Cuts Holdings in Astera Labs, Inc. $ALAB

Rhumbline Advisers lowered its stake in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 11.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 139,226 shares of the company’s stock after selling 18,658 shares during the quarter. Rhumbline Advisers’ holdings in Astera Labs were worth $27,260,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Royal Bank of Canada increased its stake in Astera Labs by 167.3% in the first quarter. Royal Bank of Canada now owns 152,453 shares of the company’s stock valued at $9,097,000 after acquiring an additional 95,409 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Astera Labs by 213.4% in the 1st quarter. AQR Capital Management LLC now owns 11,391 shares of the company’s stock worth $680,000 after purchasing an additional 7,756 shares in the last quarter. Empowered Funds LLC increased its position in shares of Astera Labs by 917.3% during the 1st quarter. Empowered Funds LLC now owns 4,639 shares of the company’s stock valued at $277,000 after purchasing an additional 4,183 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its holdings in shares of Astera Labs by 142.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 11,366 shares of the company’s stock valued at $1,028,000 after buying an additional 6,677 shares in the last quarter. Finally, CWM LLC lifted its position in Astera Labs by 79.3% in the 2nd quarter. CWM LLC now owns 6,734 shares of the company’s stock worth $609,000 after buying an additional 2,979 shares during the last quarter. 60.47% of the stock is owned by institutional investors.

Astera Labs News Summary

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Q4 results beat consensus (revenue and EPS ahead) and management gave solid Q1 guidance, supporting the growth narrative tied to AI/hyperscaler demand. ALAB Stock Dips 31% Post Q4 Earnings
• Positive Sentiment: Northland Securities reiterated an Outperform rating and published multi-quarter EPS projections plus a $195 price target — a bullish analyst signal that supports upside if execution continues. MarketBeat – Northland Estimates
• Neutral Sentiment: Several deep-dive writeups and the Q4 earnings transcript are available for investors parsing the details (growth, product cadence, Scorpio X timing). These are useful for assessing whether margin pressures are one-off or structural. Earnings Call Transcript
• Neutral Sentiment: Short-interest reports in the feed show anomalous “0 shares / NaN” values across dates — data appears erroneous and provides no reliable signal on short pressure. (Treat short-interest figures cautiously.)
• Negative Sentiment: Investors sold aggressively after management flagged margin headwinds and rising operating expenses; multiple outlets report a sharp post-earnings drop as traders re-priced the stock despite the beat. ALAB Stock Slides
• Negative Sentiment: Analyst downgrade / notes and reports of a gap-down move amplified the sell-off — negative research and headlines can pressure sentiment even when fundamentals look strong. Shares Gap Down Following Analyst Downgrade
• Negative Sentiment: Coverage pieces explain the paradox: stellar revenue growth but margin guidance and near-term opex make the print look less clean, prompting profit-taking and volatility. Why Stock Crashed Despite Strong Earnings

Insider Buying and Selling at Astera Labs

In related news, Director Manuel Alba sold 150,000 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $166.18, for a total transaction of $24,927,000.00. Following the completion of the transaction, the director owned 1,574,498 shares in the company, valued at $261,650,077.64. This represents a 8.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 12.50% of the company’s stock.

Astera Labs Trading Up 2.2%

ALAB stock opened at $129.32 on Monday. The stock has a market capitalization of $21.84 billion, a price-to-earnings ratio of 106.00, a PEG ratio of 2.54 and a beta of 1.51. The firm’s 50-day moving average price is $164.09 and its two-hundred day moving average price is $174.83. Astera Labs, Inc. has a 12-month low of $47.13 and a 12-month high of $262.90.

Astera Labs (NASDAQ:ALAB) last posted its earnings results on Tuesday, February 10th. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.07. Astera Labs had a return on equity of 16.87% and a net margin of 25.70%.The company had revenue of $270.58 million for the quarter, compared to analysts’ expectations of $249.46 million. During the same period last year, the firm earned $0.37 earnings per share. Astera Labs’s quarterly revenue was up 91.8% on a year-over-year basis. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. Equities analysts predict that Astera Labs, Inc. will post 0.34 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on ALAB shares. Royal Bank Of Canada started coverage on shares of Astera Labs in a research report on Wednesday, January 14th. They set an “outperform” rating and a $225.00 price target on the stock. JPMorgan Chase & Co. upped their price objective on shares of Astera Labs from $180.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. BNP Paribas Exane began coverage on shares of Astera Labs in a research report on Thursday, November 20th. They issued an “outperform” rating on the stock. Needham & Company LLC boosted their price target on shares of Astera Labs from $205.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Finally, Barclays set a $165.00 price objective on Astera Labs in a research note on Thursday, January 15th. Fourteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Astera Labs presently has a consensus rating of “Moderate Buy” and an average target price of $192.89.

Astera Labs Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.